According to data published in the Journal of Clinical Oncology (2008; 26:4426-34), once a week, bisphosphonate therapy improves bone density and improves turnover in prostate cancer patients with nonmetastatic disease who are on androgen deprivation therapy (ADT). A second year of bisphosphonate therapy provides additional skeletal benefit, whereas discontinuation results in bone loss and increased [...]
On the advanced prostate cancer group I moderate there has been a discussion about the health risks of using Fosamax for an extended period of time. The risks of long term therapy remains unclear and mixed. The Physicans Desk Reference (PDR) indicates they have no idea what effects Fosamax may have after four years! Fosamax [...]
Are you taking Fosamax to help combat osteoporosis? Many of us take Fosamax as one of the most common side effects of a hormone blockade (ADT) is loss of bone density. ADT causes osteoporosis, or a decrease in bone density, which diminishes bone strength. A decrease in your bone density increases your chance to suffer [...]
